Investing.com - Biogen (NASDAQ:BIIB) reported on Wednesday second quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Biogen announced earnings per share of $5.25 on revenue of $2.59B. Analysts polled by Investing.com anticipated EPS of $4.13 on revenue of $2.49B.
Biogen shares are down 8% from the beginning of the year and are trading at $220.26 , down-from-52-week-high.They are outperforming the S&P 500 which is down 17.4% from the start of the year.
Biogen follows other major Healthcare sector earnings this month
Biogen's report follows an earnings beat by UnitedHealth on Friday, who reported EPS of $5.57 on revenue of $80.33B, compared to forecasts EPS of $5.21 on revenue of $79.68B.
J&J had beat expectations on Tuesday with second quarter EPS of $2.59 on revenue of $24.02B, compared to forecast for EPS of $2.55 on revenue of $23.8B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar